BTCE-TRBC2

BTCE-TRBC2 is a bispecific T-cell engager (BTCE) developed for the treatment of T-cell malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL). It is engineered to bridge CD1a-expressing malignant T cells with TRBC2-positive normal effector T cells. The molecule is constructed using Fab fragments from an anti-CD1a antibody and an anti-TRBC2 antibody (derived from the Jovi-1 clone) linked to an Fc domain. By selectively recruiting TRBC2-positive effector cells to eliminate TRBC1-positive tumor cells, BTCE-TRBC2 aims to circumvent the 'fratricide' (self-killing) issues common with CD3-targeting engagers in T-cell cancers, while preserving approximately half of the healthy T-cell compartment. Preclinical studies have demonstrated that BTCE-TRBC2 induces potent, dose-dependent cytotoxicity against TRBC1-positive malignant cells and significantly reduces tumor burden in mouse models.